ACRV SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready JAK1 Inhibitor ACR-525

Nov 6, 2026

8-K

Acrivon Therapeutics Reports Second Quarter 2026 Financial Results and Clinical Pipeline Progress

Aug 12, 2026

8-K

Acrivon Therapeutics Stockholders Approve Amended and Restated 2022 Equity Incentive Plan

Jun 17, 2026

8-K

Acrivon Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

May 13, 2026

8-K

Acrivon Therapeutics Reports 2025 Financial Results and Clinical Progress for ACR-368 and ACR-2316

Mar 19, 2026

8-K

Acrivon Therapeutics Terminates OncoSignature Companion Diagnostic Agreement with Akoya Biosciences

Mar 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

OFFERING | Shares amount: 7,550,000 | Share price: $12.50 | Offering amount: $94,375,000.00

Nov 16, 2022

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 12, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 19, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 14, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 28, 2025

S-3

SHARE RESALE REGISTRATION | Shares amount: 15,295,000 | Warrants amount: 7,060,000 EFFECTIVE

Apr 17, 2024

S-8

Registration

Mar 29, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 22, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Miller Mary (Reporting)

Oct 26, 2026

Miller Mary (Reporting)

Oct 7, 2026

Levin Michaela (Reporting)

Sep 2, 2026

Levin Michaela (Reporting)

Sep 2, 2026

Blume-Jensen Peter (Reporting)

Aug 27, 2026

144

Form 144 - Report of proposed sale of securities

Aug 25, 2026

Other

TYPE

HEADLINE

FILED AT

Acrivon Therapeutics, Inc. Common Stock ACRV · SEC Filings